Monday January 22nd 2018

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Conclusions: These results, in a population who better resembled real-world clinical practice in terms of concomitant diseases and medications, are consistent with previous clinical trials and confirmed that the first dose administration of fingolimod is generally safe and well tolerated.Trial registration: EudraCT 2011-000770-60 (Source: BMC Neurology)

Link: 

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Leave a Comment

More from category

Government Shutdown’s Impact on People with MS
Government Shutdown’s Impact on People with MS

/About-the-Society/News/Government-Shutdown-s-Impact-on-People-with-MS [Read More]

Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases

An international team of researchers led by prof. Savvas Savvides has unraveled a crucial aspect of the molecular basis [Read More]

Kessler Foundation wins $735,000 grant for training rehabilitation researchers
Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a [Read More]

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]